Prognostic value of whole-body dynamic

18F- fluorodeoxyglucose Diffuse large B-Cell lymphoma Patlak Whole-body dynamic PET/CT

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 27 05 2023
revised: 23 08 2023
accepted: 31 08 2023
medline: 9 10 2023
pubmed: 9 10 2023
entrez: 9 10 2023
Statut: epublish

Résumé

This study aims to investigate the significance of interim whole-body dynamic This study reports the findings of 67 patients with diffuse large B-cell lymphoma (DLBCL). These patients underwent interim whole-body dynamic After a median follow-up of 18 months, 21 patients (31.3%) experienced disease recurrence or death. The cut-off values for the SUV Interim whole-body dynamic

Identifiants

pubmed: 37809527
doi: 10.1016/j.heliyon.2023.e19749
pii: S2405-8440(23)06957-8
pmc: PMC10559051
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e19749

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Am J Hematol. 2015 Nov;90(11):1041-6
pubmed: 26260224
J Nucl Med. 2020 Jan;61(1):40-45
pubmed: 31201248
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4048-4063
pubmed: 35716176
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Clin Nucl Med. 2020 May;45(5):e221-e231
pubmed: 32108696
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Nucl Med Commun. 2016 Apr;37(4):428-31
pubmed: 26629770
Cancers (Basel). 2021 Oct 18;13(20):
pubmed: 34680370
Int J Biol Macromol. 2021 Jun 1;180:739-752
pubmed: 33737188
Cancers (Basel). 2021 Mar 01;13(5):
pubmed: 33804417
Cancer Med. 2021 May;10(9):3035-3044
pubmed: 33792190
Life (Basel). 2022 Aug 30;12(9):
pubmed: 36143386
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):932-942
pubmed: 34405277
Hell J Nucl Med. 2022 May-Aug;25(2):125-131
pubmed: 35913858
J Nucl Med. 2005 Mar;46(3):424-8
pubmed: 15750154
Eur Radiol. 2019 Sep;29(9):4812-4821
pubmed: 30689031
Radiol Oncol. 2021 May 31;55(3):259-267
pubmed: 34051709
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
J Hematol Oncol. 2020 Dec 14;13(1):175
pubmed: 33317571
Oncol Lett. 2021 Feb;21(2):132
pubmed: 33552253
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1672-1679
pubmed: 29705879
Semin Nucl Med. 2023 May;53(3):371-388
pubmed: 36376131
Am J Hematol. 2019 May;94(5):604-616
pubmed: 30859597
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):501-518
pubmed: 30269154
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1298-1310
pubmed: 34651227

Auteurs

Jiankang Yin (J)

School of Basic Medical Sciences, Anhui Medical University, Hefei, PR China.

Hui Wang (H)

Department of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, Anhui, PR China.

Gan Zhu (G)

Department of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, Anhui, PR China.

Ni Chen (N)

School of Basic Medical Sciences, Anhui Medical University, Hefei, PR China.

Muhammad Imran Khan (MI)

School of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, Anhui, PR China.
Department of Pathology, District Headquarters Hospital, Jhang, 35200, Punjab Province, Pakistan.
Hefei National Lab for Physical Sciences at Microscale and the Center for Biomedical Engineering, University of Science and Technology of China, Hefei, 230026, Anhui, PR China.

Ye Zhao (Y)

School of Basic Medical Sciences, Anhui Medical University, Hefei, PR China.

Classifications MeSH